Orthopedic Biomaterials Market Size, Share and COVID-19 Impact Analysis | Europe | 2022-2028 | MedSuite | Includes: Bone Graft Substitutes, Orthopedic Growth Factors, and 3 more
- Year: 2022
- Scope: 10 Years
- Region: Europe
- Type: MedSuite
The total European orthopedic biomaterials market is growing at a rate of 2%, which will take the 2021 market value of €550 million up to €632 million by 2028.
The full report suite on the European market for orthopedic biomaterials includes bone graft substitutes, which are represented by allografts, demineralized bone matrix (DBM) and synthetic bone grafts. The report also includes orthopedic growth factors, cell therapies, hyaluronic acid (HA) viscosupplementation and cartilage repair.
MARKET REPORT DATA TYPES INCLUDED
- Unit Sales, Average Selling Prices, Market Value & Growth Trends
- Forecasts Until 2028, and Historical Data to 2018
- Market Drivers & Limiters for Each Segment
- Competitive Analysis with Market Shares for Each Segment
- Recent Mergers & Acquisitions
- Procedure Volumes
- Company Profiles, Product Portfolios and SWOT for Top Competitors
- COVID-19 Impact Analysis
EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET TRENDS
Demographic factors continue to be the largest driver within the orthopedic biomaterials market in Europe. This is primarily due to the growing elderly population, which is correlated to the incidence of osteoarthritis, osteoporosis, osteomalacia, rheumatoid arthritis and other bone diseases. As the aging population in Europe is growing alongside the majority of baby boomers reaching retirement age, the demand for bone graft substitutes will also increase. A lower level of physical activity is more common among older adults.
EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET SHARE INSIGHTS
Overall, within the European orthopedic biomaterials market there are two dominant competitors: Fidia and Medtronic.
In 2021, Fidia retained its spot as the leader within the European orthopedic biomaterials market. This is due to its orthopedic HA viscosupplementation products, Hyalubrix® and Hyalgan®, which maintained a strong presence in the market.
MARKET SEGMENTATION SUMMARY
You can view all these included reports and segmentation here:
- Bone Graft Substitutes Market – MedCore – Includes:
- Allografts, demineralized bone matrices (DBM) and synthetic bone grafts substitutes
- Orthopedic Growth Factor Market – MedCore – Includes:
- Segments for spine and tibial fracture
- Orthopedic Cell Therapy Market – MedCore – Includes:
- Platelet-rich plasma and bone marrow concentration segments
- Hyaluronic Acid Viscosupplementation Market – MedCore – Includes:
- Single-injection, Two-injection, Three-Injection, and Five-Injection products
- Orthopedic Cartilage Repair Market – MedCore — Includes:
- Osteochondral allografts, meniscal allografts, ACI products and osteochondral autografts
Global Research Scope Summary
| Report Attribute | Details |
|---|---|
| Regions | Europe |
| Base Year | 2021 |
| Forecast | 2022-2028 |
| Historical Data | 2018-2021 |
| Quantitative Coverage | Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Coverage | COVID-19 Impact, Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
| TABLE OF CONTENTS |
| LIST OF FIGURES XI |
| LIST OF CHARTS XXIII |
| EXECUTIVE SUMMARY 1 |
| EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW 1 |
| COMPETITIVE ANALYSIS 4 |
| MARKET TRENDS 7 |
| MARKET DEVELOPMENTS 9 |
| PROCEDURE NUMBERS 10 |
| MARKETS INCLUDED 12 |
| KEY REPORT UPDATES 14 |
| VERSION HISTORY 16 |
| RESEARCH METHODOLOGY 17 |
| Step 1: Project Initiation & Team Selection 17 |
| Step 2: Prepare Data Systems and Perform Secondary Research 20 |
| Step 3: Preparation for Interviews & Questionnaire Design 22 |
| Step 4: Performing Primary Research 23 |
| Step 5: Research Analysis: Establishing Baseline Estimates 25 |
| Step 6: Market Forecast and Analysis 26 |
| Step 7: Identify Strategic Opportunities 28 |
| Step 8: Final Review and Market Release 29 |
| Step 9: Customer Feedback and Market Monitoring 30 |
| IMPACT OF COVID-19 ON THE EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET 31 |
| 2.1 INTRODUCTION 31 |
| 2.1.1 Treatable Population 32 |
| 2.2 COUNTRY PROFILES 33 |
| 2.3 ANALYSIS BY MARKET SEGMENT 34 |
| 2.3.1 Worst Case Scenario 34 |
| 2.3.2 Base Case Scenario 35 |
| 2.3.3 Best Case Scenario 36 |
| PRODUCT ASSESSMENT 38 |
| 3.1 INTRODUCTION 38 |
| 3.2 PRODUCT PORTFOLIOS 38 |
| 3.2.1 Bone Graft Substitutes 39 |
| 3.2.2 Growth Factors 45 |
| 3.2.2.1.1 NELL-1 Bone Biologics 46 |
| 3.2.2.1.2 INFUSE® by Medtronic 46 |
| 3.2.2.1.3 OsteoAMP® by Bioventus Surgical 47 |
| 3.2.2.1.4 OP-1™ by Stryker / Olympus Biotech (delisted) 47 |
| 3.2.2.1.5 The Osteogrow Study 47 |
| 3.2.2.2 Other Products 48 |
| 3.2.2.2.1 AUGMENT® Bone Graft 48 |
| 3.2.2.2.2 Amplex® Osteobiologic Bone Graft Substitute 49 |
| 3.2.2.2.3 i-Factor™ Peptide Bone Matrix 49 |
| 3.2.3 Cellular Allografts (Stem Cell) 51 |
| 3.2.4 Cell Therapy 55 |
| 3.2.4.1 Platelet-Rich Plasma 56 |
| 3.2.4.2 Bone Marrow Aspirate Concentrate 57 |
| 3.2.5 Hyaluronic Acid Viscosupplementation (HAV) 59 |
| 3.2.6 Cartilage Repair 61 |
| 3.3 REGULATORY ISSUES AND RECALLS 63 |
| 3.3.1 Bioventus 63 |
| 3.3.1.1 Bone Graft Substitute 63 |
| 3.3.2 Exactech 63 |
| 3.3.2.1 Bone Graft Substitute 63 |
| 3.3.3 Medtronic 64 |
| 3.3.3.1 Bone Graft Substitute 64 |
| 3.3.4 Sanofi 64 |
| 3.3.4.1 Hyaluronic Acid Viscosupplementation 64 |
| 3.3.5 Wright Medical (Stryker) 65 |
| 3.3.5.1 Bone Graft Substitute 65 |
| 3.3.6 Xtant 65 |
| 3.3.6.1 Bone Graft Substitute 65 |
| 3.3.7 Zimmer Biomet 66 |
| 3.3.7.1 Growth Factor 66 |
| 3.4 CLINICAL TRIALS 67 |
| 3.4.1 Arthrex 67 |
| 3.4.1.1 Bone Graft Substitute 67 |
| 3.4.2 DePuy Synthes 68 |
| 3.4.2.1 Cellular Allograft 68 |
| 3.4.3 RTI Surgical 69 |
| 3.4.3.1 Bone Graft Substitute 69 |
| 3.4.4 Stryker 70 |
| 3.4.4.1 Bone Graft Substitute 70 |
| 3.4.5 Others 71 |
| 3.4.5.1 Bone Graft Substitute 71 |
| 3.4.5.2 Growth Factor 72 |
| 3.4.5.3 Cellular Allograft 73 |
| 3.4.5.4 Cell Therapy 74 |
| 3.4.5.5 Hyaluronic Acid Viscosupplementation 76 |
| 3.4.5.6 Cartilage Repair 76 |
| EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW 78 |
| 4.1 INTRODUCTION 78 |
| 4.2 CURRENCY EXCHANGE RATE 82 |
| 4.3 MARKET OVERVIEW & TREND ANALYSIS 83 |
| 4.4 DRIVERS AND LIMITERS 88 |
| 4.4.1 Market Drivers 88 |
| 4.4.2 Market Limiters 89 |
| 4.5 COMPETITIVE MARKET SHARE ANALYSIS 90 |
| 4.6 MERGERS AND ACQUISITIONS 97 |
| 4.7 COMPANY PROFILES 98 |
| 4.7.1 Arthrex 98 |
| 4.7.2 Bioventus 99 |
| 4.7.3 DePuy Synthes 100 |
| 4.7.4 Ferring Pharmaceuticals 101 |
| 4.7.5 Fidia Farmaceutici 102 |
| 4.7.6 Harvest Technologies (Terumo BCT) 103 |
| 4.7.7 Medtronic 104 |
| 4.7.8 Musculoskeletal Transplant Foundation (MTF) 106 |
| 4.7.9 NuVasive 107 |
| 4.7.10 Orthofix 108 |
| 4.7.11 RTI Surgical 109 |
| 4.7.12 Sanofi 110 |
| 4.7.13 Stryker 111 |
| 4.7.14 Vericel Corporation 112 |
| 4.7.15 Zimmer Biomet 113 |
| 4.8 SWOT ANALYSIS 115 |
| 4.8.1 Arthrex 116 |
| 4.8.2 Bioventus 117 |
| 4.8.3 DePuy Synthes 118 |
| 4.8.4 Ferring Pharmaceuticals 119 |
| 4.8.5 Fidia Farmaceutici 120 |
| 4.8.6 Harvest Technologies (Terumo BCT) 121 |
| 4.8.7 Medtronic 122 |
| 4.8.8 Musculoskeletal Transplant Foundation (MTF) 123 |
| 4.8.9 NuVasive 124 |
| 4.8.10 Orthofix 125 |
| 4.8.11 RTI Surgical 126 |
| 4.8.12 Sanofi 127 |
| 4.8.13 Stryker 128 |
| 4.8.14 Vericel 129 |
| 4.8.15 Zimmer Biomet 130 |
| COUNTRY PROFILES 131 |
| 5.1 INTRODUCTION 131 |
| 5.1.1 GDP Per Capita 131 |
| 5.1.2 Price Index 131 |
| 5.2 GERMANY 132 |
| 5.3 FRANCE 133 |
| 5.4 UNITED KINGDOM 134 |
| 5.5 ITALY 135 |
| 5.6 SPAIN 136 |
| 5.7 BENELUX 137 |
| 5.8 SCANDINAVIA 138 |
| 5.9 AUSTRIA 139 |
| 5.10 SWITZERLAND 140 |
| 5.11 PORTUGAL 141 |
| PROCEDURE NUMBERS 142 |
| 6.1 INTRODUCTION 142 |
| 6.2 PROCEDURES 143 |
| 6.2.1 Orthopedic Bone Grafting Procedures 145 |
| 6.2.1.1 Orthopedic Bone Grafting Procedures by Material 147 |
| 6.2.1.2 Orthopedic Bone Grafting Procedures by Indication 148 |
| 6.2.1.2.1 Average Units Used per Procedure by Indication 160 |
| 6.2.1.3 Allograft Procedures by Indication 161 |
| 6.2.1.4 DBM Procedures by Indication 173 |
| 6.2.1.5 Synthetic Procedures by Indication 180 |
| 6.2.1.6 Orthopedic Bone Grafting Procedures by Care Setting 192 |
| 6.2.2 Orthopedic Growth Factor Procedures 193 |
| 6.2.2.1 Orthopedic Growth Factor Procedures by Indication 195 |
| 6.2.2.2 Orthopedic Growth Factor Procedures by Care Setting 198 |
| 6.2.3 Orthopedic Cell Therapy Procedures 199 |
| 6.2.3.1 Orthopedic Cell Therapy Procedures by Material Type 201 |
| 6.2.3.2 Platelet-Rich Plasma Procedures 202 |
| 6.2.3.3 Bone Marrow Aspirate Concentrate Procedures 203 |
| 6.2.3.1 Orthopedic Cell Therapy Procedures by Care Setting 204 |
| 6.2.4 Hyaluronic Acid Viscosupplementation Procedures 205 |
| 6.2.4.1 Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle 207 |
| 6.2.4.1 Hyaluronic Acid Viscosupplementation Procedures by Care Setting 213 |
| 6.2.5 Orthopedic Cartilage Repair Procedures 214 |
| 6.2.5.1 Orthopedic Cartilage Repair Procedures by Type 215 |
| 6.2.5.2 Orthopedic Cartilage Repair Procedures by Care Setting 217 |
| ORTHOPEDIC BONE GRAFT SUBSTITUTE MARKET 218 |
| 7.1 INTRODUCTION 218 |
| 7.2 MARKET OVERVIEW 220 |
| 7.3 MARKET ANALYSIS AND FORECAST 224 |
| 7.3.1 Total Bone Graft Substitute Market 224 |
| 7.3.2 Allograft Bone Graft Substitute Market 230 |
| 7.3.3 Demineralized Bone Matrix Bone Graft Substitute Market 237 |
| 7.3.4 Synthetic Bone Graft Substitute Market 244 |
| 7.4 UNIT ANALYSIS 251 |
| 7.4.1 Total Bone Graft Substitute Unit Analysis 252 |
| 7.4.2 Allograft Bone Graft Substitute Unit Analysis 254 |
| 7.4.2.1 Allograft Bone Graft Substitute Units Sold by Indication 254 |
| 7.4.2.1.1 Spine Allograft Bone Graft Substitute Units Sold by Anatomy 255 |
| 7.4.2.1.2 Trauma Allograft Bone Graft Substitute Units Sold by Anatomy 258 |
| 7.4.2.1.3 Large Joint Reconstruction Allograft Bone Graft Substitute Units Sold by Anatomy 261 |
| 7.4.2.1.4 Foot Reconstruction Allograft Bone Graft Substitute Units Sold 264 |
| 7.4.2.1.5 Craniomaxillofacial Allograft Bone Graft Substitute Units Sold 265 |
| 7.4.2.1.6 Oncology Allograft Bone Graft Substitute Units Sold 266 |
| 7.4.3 Demineralized Bone Matrix Allograft Unit Analysis 267 |
| 7.4.3.1 Demineralized Bone Matrix Allograft Units Sold by Indication 267 |
| 7.4.3.1.1 Spine Demineralized Bone Matrix Allograft Units Sold by Anatomy 268 |
| 7.4.3.1.2 Trauma Demineralized Bone Matrix Allograft Units Sold by Anatomy 271 |
| 7.4.3.1.3 Craniomaxillofacial Demineralized Bone Matrix Allograft Units Sold 274 |
| 7.4.4 Synthetic Bone Graft Substitute Unit Analysis 275 |
| 7.4.4.1 Synthetic Bone Graft Substitute Units Sold by Indication 275 |
| 7.4.4.1.1 Spine Synthetic Bone Graft Substitute Units Sold by Anatomy 276 |
| 7.4.4.1.2 Trauma Synthetic Bone Graft Substitute Units Sold by Anatomy 279 |
| 7.4.4.1.3 Large Joint Reconstruction Synthetic Bone Graft Substitute Units Sold by Anatomy 282 |
| 7.4.4.1.4 Foot Reconstruction Synthetic Bone Graft Substitute Units Sold 285 |
| 7.4.4.1.5 Craniomaxillofacial Synthetic Bone Graft Substitute Units Sold 286 |
| 7.4.4.1.6 Oncology Synthetic Bone Graft Substitute Units Sold 287 |
| 7.5 DRIVERS AND LIMITERS 288 |
| 7.5.1 Market Drivers 288 |
| 7.5.2 Market Limiters 289 |
| 7.6 COMPETITIVE MARKET SHARE ANALYSIS 291 |
| ORTHOPEDIC GROWTH FACTOR MARKET 296 |
| 8.1 INTRODUCTION 296 |
| 8.1.1 BMP-2 (Medtronic) 297 |
| 8.2 MARKET OVERVIEW 298 |
| 8.3 MARKET ANALYSIS AND FORECAST 301 |
| 8.3.1 Orthopedic Growth Factor Market 301 |
| 8.4 UNIT ANALYSIS 308 |
| 8.4.1 Spine Orthopedic Growth Factor Unit Analysis 308 |
| 8.4.2 Tibial Fracture Orthopedic Growth Factor Unit Analysis 310 |
| 8.5 DRIVERS AND LIMITERS 312 |
| 8.5.1 Market Drivers 312 |
| 8.5.2 Market Limiters 312 |
| 8.6 COMPETITIVE MARKET SHARE ANALYSIS 314 |
| ORTHOPEDIC CELL THERAPY MARKET 316 |
| 9.1 INTRODUCTION 316 |
| 9.2 MARKET OVERVIEW 320 |
| 9.3 MARKET ANALYSIS AND FORECAST 324 |
| 9.3.1 Platelet-Rich Plasma Market 324 |
| 9.3.2 Bone Marrow Aspirate Concentrate Market 331 |
| 9.4 UNIT ANALYSIS 338 |
| 9.4.1 Platelet-Rich Plasma Units Sold by Indication 338 |
| 9.4.1.1 Soft Tissue Platelet-Rich Plasma Units Sold 339 |
| 9.4.1.2 Spine Platelet-Rich Plasma Units Sold 340 |
| 9.4.1.3 Cardiac Platelet-Rich Plasma Units Sold 341 |
| 9.4.1.4 Orthopedic Platelet-Rich Plasma Units Sold 342 |
| 9.4.1.5 Plastics Platelet-Rich Plasma Units Sold 343 |
| 9.4.2 Bone Marrow Aspirate Concentrate Units Sold by Indication 344 |
| 9.4.2.1 Spine Bone Marrow Aspirate Concentrate Units Sold 345 |
| 9.4.2.2 Soft Tissue Bone Marrow Aspirate Concentrate Units Sold 346 |
| 9.4.2.3 Trauma Bone Marrow Aspirate Concentrate Units Sold 347 |
| 9.4.2.4 Joint Reconstruction Bone Marrow Aspirate Concentrate Units Sold 348 |
| 9.5 DRIVERS AND LIMITERS 349 |
| 9.5.1 Market Drivers 349 |
| 9.5.2 Market Limiters 350 |
| 9.6 COMPETITIVE MARKET SHARE ANALYSIS 351 |
| HYALURONIC ACID VISCOSUPPLEMENTATION MARKET 354 |
| 10.1 INTRODUCTION 354 |
| 10.1.1 Benefits of Viscosupplementation 355 |
| 10.1.2 Synovial Fluid 355 |
| 10.1.3 Product Types 356 |
| 10.2 MARKET OVERVIEW 357 |
| 10.3 MARKET ANALYSIS AND FORECAST 361 |
| 10.3.1 Total Hyaluronic Acid Viscosupplementation Market 361 |
| 10.3.2 Single-Injection Hyaluronic Acid Viscosupplementation Market 368 |
| 10.3.3 Two-Injection Hyaluronic Acid Viscosupplementation Market 375 |
| 10.3.4 Three-Injection Hyaluronic Acid Viscosupplementation Market 381 |
| 10.3.5 Five-Injection Hyaluronic Acid Viscosupplementation Market 387 |
| 10.4 DRIVERS AND LIMITERS 394 |
| 10.4.1 Market Drivers 394 |
| 10.4.2 Market Limiters 395 |
| 10.5 COMPETITIVE MARKET SHARE ANALYSIS 396 |
| ORTHOPEDIC CARTILAGE REPAIR MARKET 401 |
| 11.1 INTRODUCTION 401 |
| 11.1.1 Anatomy 401 |
| 11.1.2 Methods for Cartilage Repair 401 |
| 11.1.2.1 Osteochondral Allograft Transfer 401 |
| 11.1.2.2 Autologous Chondrocyte Implantation (ACI) 402 |
| 11.1.2.3 Meniscal Allograft Transplantation 402 |
| 11.1.2.4 Osteochondral Autograft 402 |
| 11.2 MARKET OVERVIEW 403 |
| 11.3 MARKET ANALYSIS AND FORECAST 406 |
| 11.3.1 Osteochondral Allograft Market 406 |
| 11.3.2 Meniscal Allograft Market 407 |
| 11.3.3 Autologous Chondrocyte Implantation Market 408 |
| 11.3.4 Osteochondral Autograft Market 415 |
| 11.4 DRIVERS AND LIMITERS 416 |
| 11.4.1 Market Drivers 416 |
| 11.4.2 Market Limiters 417 |
| 11.5 COMPETITIVE MARKET SHARE ANALYSIS 418 |
| ABBREVIATIONS 421 |
| Adistem | DePuy Synthes |
| Alphatec | Documedica |
| Anika Therapeutics | Exactech |
| Arthrex | Ferring |
| Baxter | Fidia |
| BioCell | Finceramica |
| Biocomposites | Geistlich |
| Bioiberica | Harvest (Terumo) |
| Biomatlante | IBSA Pharma |
| Bioventus | Integra LifeSciences |
| Bonalive | Isto |
| Cerapedics | Kuros |
| CO.DON | LCA Pharmaceuticals |
| CONMED | Medtronic |
| Croma-Pharma | NovaBone |
| Curasan | Nuo Therapeutics |
| LIST OF CHARTS |
| Chart 1 1: Orthopedic Biomaterials Market by Segment, Europe, 2021 – 2028 3 |
| Chart 1 2: Orthopedic Biomaterials Market Overview, Europe, 2021 & 2028 3 |
| Chart 2 1: Multi-Scenario Orthopedic Biomaterials Market Forecast, Europe, 2018 – 2028 (€M) 37 |
| Chart 4 1: Orthopedic Biomaterials Market by Segment, Europe, 2018 – 2028 87 |
| Chart 4 2: Leading Competitors, Orthopedic Biomaterials Market, Europe, 2021 96 |
| Chart 5 1: Country Profile, Germany, 2021 132 |
| Chart 5 2: Country Profile, France, 2021 133 |
| Chart 5 3: Country Profile, United Kingdom, 2021 134 |
| Chart 5 4: Country Profile, Italy, 2021 135 |
| Chart 5 5: Country Profile, Spain, 2021 136 |
| Chart 5 6: Country Profile, Benelux, 2021 137 |
| Chart 5 7: Country Profile, Scandinavia, 2021 138 |
| Chart 5 8: Country Profile, Austria, 2021 139 |
| Chart 5 9: Country Profile, Switzerland, 2021 140 |
| Chart 5 10: Country Profile, Portugal, 2021 141 |
| Chart 7 1: Bone Graft Substitute Market by Segment, Europe, 2018 – 2028 223 |
| Chart 7 2: Leading Competitors, Orthopedic Bone Graft Substitute Market, Europe, 2021 295 |
| Chart 9 1: Orthopedic Cell Therapy Market by Segment, Europe, 2018 – 2028 323 |
| Chart 9 2: Leading Competitors, Orthopedic Cell Therapy Market, Europe, 2021 353 |
| Chart 10 1: Hyaluronic Acid Viscosupplementation Market by Segment, Europe, 2018 – 2028 360 |
| Chart 10 2: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, Europe, 2021 400 |
| Chart 11 1: Orthopedic Cartilage Repair Market by Segment, Europe, 2018 – 2028 405 |
| Chart 11 2: Leading Competitors, Orthopedic Cartilage Repair Market, Europe, 2021 420 |
| LIST OF FIGURES |
| Figure 1 1: Orthopedic Biomaterials Market Share Ranking by Segment, Europe, 2021 4 |
| Figure 1 2: Companies Researched in this Report (1 of 2) 5 |
| Figure 1 3: Companies Researched in this Report (2 of 2) 6 |
| Figure 1 4: Factors Impacting the Orthopedic Biomaterials Market by Segment, Europe (1 of 2) 7 |
| Figure 1 5: Factors Impacting the Orthopedic Biomaterials Market by Segment, Europe (2 of 2) 8 |
| Figure 1 6: Recent Events in the Orthopedic Biomaterials Market, Europe, 2018 – 2021 9 |
| Figure 1 7: Orthopedic Biomaterials Procedures Covered, Europe (1 of 2) 10 |
| Figure 1 8: Orthopedic Biomaterials Procedures Covered, Europe (2 of 2) 11 |
| Figure 1 9: Orthopedic Biomaterials Markets Covered, Europe (1 of 2) 12 |
| Figure 1 10: Orthopedic Biomaterials Markets Covered, Europe (2 of 2) 13 |
| Figure 1 11: Key Report Updates (1 of 2) 14 |
| Figure 1 12: Key Report Updates (2 of 2) 15 |
| Figure 1 13: Version History 16 |
| Figure 2 1: Orthopedic Biomaterials Market by Segment, Worst Case Scenario, Europe, 2018 – 2028 (€M) 34 |
| Figure 2 2: Orthopedic Biomaterials Market by Segment, Base Case Scenario, Europe, 2018 – 2028 (€M) 35 |
| Figure 2 3: Orthopedic Biomaterials Market by Segment, Best Case Scenario, Europe, 2018 – 2028 (€M) 36 |
| Figure 3 1: Bone Graft Substitutes Products by Company (1 of 4) 41 |
| Figure 3 2: Bone Graft Substitutes Products by Company (2 of 4) 42 |
| Figure 3 3: Bone Graft Substitutes Products by Company (3 of 4) 43 |
| Figure 3 4: Bone Graft Substitutes Products by Company (4 of 4) 44 |
| Figure 3 5: Growth Factor Products by Company 50 |
| Figure 3 6: Estimates of Funding for Stem Cell Research 53 |
| Figure 3 7: Cellular Allograft Products by Company 54 |
| Figure 3 8: Cell Therapy Products by Company 58 |
| Figure 3 9: Hyaluronic Acid Viscosupplementation by Products by Company 60 |
| Figure 3 10: Cartilage Repair Products by Company 62 |
| Figure 3 11: Class 2 Device Recall Bioactive Bone Graft Putty 63 |
| Figure 3 12: Class 2 Device Recall Opteform Allograft Disc 63 |
| Figure 3 13: Class 2 Device Recall INFUSE Bone Graft X SMALL KIT 64 |
| Figure 3 14: Class 2 Device Recall SynviscOne 64 |
| Figure 3 15: Class 2 Device Recall PROSTIM 10cc INJECTABLE 65 |
| Figure 3 16: Class 2 Device Recall OsteoSelect Demineralized Bone Matrix (DBM) Putty 65 |
| Figure 3 17: Class 1 Device Recall EBI Osteogen Implantable Bone Growth Stimulator 66 |
| Figure 2-18: Demineralized Bone Matrix Rotator Cuff Study 67 |
| Figure 2-19: ViviGen Cellular Bone Matrix for Hindfoot or Ankle Arthrodesis (ViviGen) 68 |
| Figure 2-20: Clinical Outcomes Associated With the Use of ViviGen® for the Treatment of Lumbar Degenerative Disc Disease (ViviGen) 68 |
| Figure 2-21: Prospective SPINE Registry (SPINE) 69 |
| Figure 2-22: ACDF Using Structural Allograft vs. Tritanium C 70 |
| Figure 2-23: Long-term Safety and Effectiveness of AUGMENT® Injectable Bone Graft Compared to Autologous Bone Graft 71 |
| Figure 2-24: Rate of Bony Fusion Using NanoBone® Synthetic Bone Graft Versus Local Autologous Bone Graft. (BONE) 71 |
| Figure 2-25: Novel Porous Bioceramic Material as a Bone Substitute 72 |
| Figure 2-26: Evaluation of the Effectiveness of AMPLEX® Compared to Autogenous Bone Grafts 72 |
| Figure 2-27: Safety, Efficacy, & Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care 73 |
| Figure 2-28: Bone Marrow Aspirate Concentrate Use in Hip Osteoarthritis (BMAC) 74 |
| Figure 2-29: A Prospective Study of Clinical Outcomes Following a Single Intradiscal Injection of Bone Marrow Aspirate Concentrate (BMAC) for Single Level Discogenic Low Back Pain 74 |
| Figure 2-30: Platelet-Rich Plasma (PRP) for Treatment of Symptomatic Lumbar Facet Syndrome of the Spine 75 |
| Figure 2-31: Bone Marrow Aspirate Concentrate (BMAC)Treatment for Knee Osteoarthritis (BMAC) 75 |
| Figure 2-32: The Effectiveness of Different Doses of Hyaluronic Acid Injections in Knee Osteoarthritis. 76 |
| Figure 2-33: Osteochondral Allograft in the Surgical Treatment of Basal Joint Arthritis 76 |
| Figure 2-34: Prospective Evaluation of ProChondrix CR for Repair of Articular Cartilage Defects on Femoral Condyle and Patella 77 |
| Figure 2-35: Phase 2 Clinical Trial of CartiLife® in the United States 77 |
| Figure 4 1: Currency Exchange Rate, 2021 82 |
| Figure 4 2: Orthopedic Biomaterials Market by Segment, Europe, 2018 – 2028 (€M) 85 |
| Figure 4 3: Orthopedic Biomaterials Market by Segment, Europe, 2018 – 2028 (US$M) 86 |
| Figure 4 4: Leading Competitors, Orthopedic Biomaterials Market, Europe, 2021 (1 of 2) 94 |
| Figure 4 5: Leading Competitors, Orthopedic Biomaterials Market, Europe, 2021 (2 of 2) 95 |
| Figure 4 6: SWOT Analysis, Arthrex 116 |
| Figure 4 7: SWOT Analysis, Bioventus 117 |
| Figure 4 8: SWOT Analysis, DePuy Synthes 118 |
| Figure 4 9: SWOT Analysis, Ferring Pharmaceuticals 119 |
| Figure 4 10: SWOT Analysis, Fidia Farmaceutici 120 |
| Figure 4 11: SWOT Analysis, Harvest Technologies 121 |
| Figure 4 12: SWOT Analysis, Medtronic 122 |
| Figure 4 13: SWOT Analysis, MTF 123 |
| Figure 4 14: SWOT Analysis, NuVasive 124 |
| Figure 4 15: SWOT Analysis, Orthofix 125 |
| Figure 4 16: SWOT Analysis, RTI Surgical 126 |
| Figure 4 17: SWOT Analysis, Genzyme (Sanofi) 127 |
| Figure 4 18: SWOT Analysis, Stryker 128 |
| Figure 4 19: SWOT Analysis, Vericel Corporation 129 |
| Figure 4 20: SWOT Analysis, Zimmer Biomet 130 |
| Figure 6 1: Orthopedic Biomaterials Procedures by Segment, Europe, 2018 – 2028 143 |
| Figure 6 2: Orthopedic Biomaterials Procedures by Segment, Europe, 2018 – 2028 144 |
| Figure 6 3: Orthopedic Bone Grafting Procedures by Country, Europe, 2018 – 2028 146 |
| Figure 6 4: Orthopedic Bone Grafting Procedures by Material, Europe, 2018 – 2028 147 |
| Figure 6 5: Orthopedic Bone Grafting Procedures by Indication, Europe, 2018 – 2028 (1 of 2) 149 |
| Figure 6 6: Orthopedic Bone Grafting Procedures by Indication, Europe, 2018 – 2028 (2 of 2) 150 |
| Figure 6 7: Cervical Spine Procedures by Country, Europe, 2018 – 2028 151 |
| Figure 6 8: Thoracolumbar Spine Procedures by Country, Europe, 2018 – 2028 152 |
| Figure 6 9: Non-Union Trauma Procedures by Country, Europe, 2018 – 2028 153 |
| Figure 6 10: Fresh Fracture Trauma Procedures by Country, Europe, 2018 – 2028 154 |
| Figure 6 11: Hip Procedures by Country, Europe, 2018 – 2028 155 |
| Figure 6 12: Knee Procedures by Country, Europe, 2018 – 2028 156 |
| Figure 6 13: Foot Procedures by Country, Europe, 2018 – 2028 157 |
| Figure 6 14: Craniomaxillofacial Procedures by Country, Europe, 2018 – 2028 158 |
| Figure 6 15: Oncology Procedures by Country, Europe, 2018 – 2028 159 |
| Figure 6 16: Average Units Used per Procedure by Indication, Europe, 2018 – 2028 160 |
| Figure 6 17: Allograft Procedures by Country, Europe, 2018 – 2028 161 |
| Figure 6 18: Allograft Procedures by Indication, Europe, 2018 – 2028 (1 of 2) 162 |
| Figure 6 19: Allograft Procedures by Indication, Europe, 2018 – 2028 (2 of 2) 163 |
| Figure 6 20: Allograft Cervical Spine Procedures by Country, Europe, 2018 – 2028 164 |
| Figure 6 21: Allograft Thoracolumbar Spine Procedures by Country, Europe, 2018 – 2028 165 |
| Figure 6 22: Allograft Non-Union Trauma Procedures by Country, Europe, 2018 – 2028 166 |
| Figure 6 23: Allograft Fresh Fracture Trauma Procedures by Country, Europe, 2018 – 2028 167 |
| Figure 6 24: Allograft Hip Procedures by Country, Europe, 2018 – 2028 168 |
| Figure 6 25: Allograft Knee Procedures by Country, Europe, 2018 – 2028 169 |
| Figure 6 26: Allograft Foot Procedures by Country, Europe, 2018 – 2028 170 |
| Figure 6 27: Allograft Craniomaxillofacial Procedures by Country, Europe, 2018 – 2028 171 |
| Figure 6 28: Allograft Oncology Procedures by Country, Europe, 2018 – 2028 172 |
| Figure 6 29: DBM Procedures by Country, Europe, 2018 – 2028 173 |
| Figure 6 30: DBM Procedures by Indication, Europe, 2018 – 2028 174 |
| Figure 6 31: DBM Cervical Spine Procedures by Country, Europe, 2018 – 2028 175 |
| Figure 6 32: DBM Thoracolumbar Spine Procedures by Country, Europe, 2018 – 2028 176 |
| Figure 6 33: DBM Non-Union Trauma Procedures by Country, Europe, 2018 – 2028 177 |
| Figure 6 34: DBM Fresh Fracture Trauma Procedures by Country, Europe, 2018 – 2028 178 |
| Figure 6 35: DBM Craniomaxillofacial Procedures by Country, Europe, 2018 – 2028 179 |
| Figure 6 36: Synthetic Procedures by Country, Europe, 2018 – 2028 180 |
| Figure 6 37: Synthetic Procedures by Indication, Europe, 2018 – 2028 (1 of 2) 181 |
| Figure 6 38: Synthetic Procedures by Indication, Europe, 2018 – 2028 (2 of 2) 182 |
| Figure 6 39: Synthetic Cervical Spine Procedures by Country, Europe, 2018 – 2028 183 |
| Figure 6 40: Synthetic Thoracolumbar Spine Procedures by Country, Europe, 2018 – 2028 184 |
| Figure 6 41: Synthetic Non-Union Trauma Procedures by Country, Europe, 2018 – 2028 185 |
| Figure 6 42: Synthetic Fresh Fracture Trauma Procedures by Country, Europe, 2018 – 2028 186 |
| Figure 6 43: Synthetic Hip Procedures by Country, Europe, 2018 – 2028 187 |
| Figure 6 44: Synthetic Knee Procedures by Country, Europe, 2018 – 2028 188 |
| Figure 6 45: Synthetic Foot Procedures by Country, Europe, 2018 – 2028 189 |
| Figure 6 46: Synthetic Craniomaxillofacial Procedures by Country, Europe, 2018 – 2028 190 |
| Figure 6 47: Synthetic Oncology Procedures by Country, Europe, 2018 – 2028 191 |
| Figure 6 48: Orthopedic Bone Grafting Procedures by Care Setting, Europe, 2018 – 2028 192 |
| Figure 6 49: Orthopedic Growth Factor Procedures by Country, Europe, 2018 – 2028 194 |
| Figure 6 50: Orthopedic Growth Factor Procedures by Indication, Europe, 2018 – 2028 195 |
| Figure 6 51: Spine Growth Factor Procedures by Country, Europe, 2018 – 2028 196 |
| Figure 6 52: Trauma Growth Factor Procedures by Country, Europe, 2018 – 2028 197 |
| Figure 6 53: Orthopedic Growth Factor Procedures by Care Setting, Europe, 2018 – 2028 198 |
| Figure 6 54: Orthopedic Cell Therapy Procedures by Country, Europe, 2018 – 2028 200 |
| Figure 6 55: Orthopedic Cell Therapy Procedures by Material Type, Europe, 2018 – 2028 201 |
| Figure 6 56: Platelet-Rich Plasma Procedures by Country, Europe, 2018 – 2028 202 |
| Figure 6 57: Bone Marrow Aspirate Concentrate Procedures by Indication, Europe, 2018 – 2028 203 |
| Figure 6 58: Orthopedic Cell Therapy Procedures by Care Setting, Europe, 2018 – 2028 204 |
| Figure 6 59: Hyaluronic Acid Viscosupplementation Total Injections by Country, Europe, 2018 – 2028 206 |
| Figure 6 60: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, Europe, 2018 – 2028 (1 of 2) 207 |
| Figure 6 61: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, Europe, 2018 – 2028 (2 of 2) 208 |
| Figure 6 62: Single-Injection Cycles by Country, Europe, 2018 – 2028 209 |
| Figure 6 63: Two-Injection Cycles by Country, Europe, 2018 – 2028 210 |
| Figure 6 64: Three-Injection Cycles by Country, Europe, 2018 – 2028 211 |
| Figure 6 65: Five-Injection Cycles by Country, Europe, 2018 – 2028 212 |
| Figure 6 66: Hyaluronic Acid Viscosupplementation Procedures by Care Setting, Europe, 2018 – 2028 213 |
| Figure 6 67: Orthopedic Cartilage Repair Procedures by Type, Europe, 2018 – 2028 (1 of 2) 215 |
| Figure 6 68: Autologous Chondrocyte Implantation Procedures by Country, Europe, 2018 – 2028 216 |
| Figure 6 69: Orthopedic Cartilage Repair Procedures by Care Setting, Europe, 2018 – 2028 217 |
| Figure 7 1: Bone Graft Substitute Market by Segment, Europe, 2018 – 2028 (€M) 221 |
| Figure 7 2: Bone Graft Substitute Market by Segment, Europe, 2018 – 2028 (US$M) 222 |
| Figure 7 3: Total Bone Graft Substitute Market, Europe, 2018 – 2028 224 |
| Figure 7 4: Units Sold by Country, Total Bone Graft Substitute Market, Europe, 2018 – 2028 225 |
| Figure 7 5: Average Selling Price by Country, Total Bone Graft Substitute Market, Europe, 2018 – 2028 (€) 226 |
| Figure 7 6: Average Selling Price by Country, Total Bone Graft Substitute Market, Europe, 2018 – 2028 (US$) 227 |
| Figure 7 7: Market Value by Country, Total Bone Graft Substitute Market, Europe, 2018 – 2028 (€M) 228 |
| Figure 7 8: Market Value by Country, Total Bone Graft Substitute Market, Europe, 2018 – 2028 (US$M) 229 |
| Figure 7 9: Allograft Market, Europe, 2018 – 2028 231 |
| Figure 7 10: Units Sold by Country, Allograft Market, Europe, 2018 – 2028 232 |
| Figure 7 11: Average Selling Price by Country, Allograft Market, Europe, 2018 – 2028 (€) 233 |
| Figure 7 12: Average Selling Price by Country, Allograft Market, Europe, 2018 – 2028 (US$) 234 |
| Figure 7 13: Market Value by Country, Allograft Market, Europe, 2018 – 2028 (€M) 235 |
| Figure 7 14: Market Value by Country, Allograft Market, Europe, 2018 – 2028 (US$M) 236 |
| Figure 7 15: Demineralized Bone Matrix Market, Europe, 2018 – 2028 238 |
| Figure 7 16: Units Sold by Country, Demineralized Bone Matrix Market, Europe, 2018 – 2028 239 |
| Figure 7 17: Average Selling Price by Country, Demineralized Bone Matrix Market, Europe, 2018 – 2028 (€) 240 |
| Figure 7 18: Average Selling Price by Country, Total Demineralized Bone Matrix Market, Europe, 2018 – 2028 (US$) 241 |
| Figure 7 19: Market Value by Country, Total Demineralized Bone Matrix Market, Europe, 2018 – 2028 (€M) 242 |
| Figure 7 20: Market Value by Country, Total Demineralized Bone Matrix Market, Europe, 2018 – 2028 (US$M) 243 |
| Figure 7 21: Synthetic Market, Europe, 2018 – 2028 245 |
| Figure 7 22: Units Sold by Country, Synthetic Market, Europe, 2018 – 2028 246 |
| Figure 7 23: Average Selling Price by Country, Total Synthetic Market, Europe, 2018 – 2028 (€) 247 |
| Figure 7 24: Average Selling Price by Country, Total Synthetic Market, Europe, 2018 – 2028 (US$) 248 |
| Figure 7 25: Market Value by Country, Total Synthetic Market, Europe, 2018 – 2028 (€M) 249 |
| Figure 7 26: Market Value by Country, Total Synthetic Market, Europe, 2018 – 2028 (US$M) 250 |
| Figure 7 27: Total Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 (1 of 2) 252 |
| Figure 7 28: Total Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 (2 of 2) 253 |
| Figure 7 29: Allograft Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 254 |
| Figure 7 30: Spine Allograft Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 255 |
| Figure 7 31: Units Sold by Country, Cervical Spine Allograft Bone Graft Substitute, Europe, 2018 – 2028 256 |
| Figure 7 32: Units Sold by Country, Thoracolumbar Spine Allograft Bone Graft Substitute, Europe, 2018 – 2028 257 |
| Figure 7 33: Trauma Allograft Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 258 |
| Figure 7 34: Units Sold by Country, Non-Union Trauma Allograft Bone Graft Substitute, Europe, 2018 – 2028 259 |
| Figure 7 35: Units Sold by Country, Fresh Fracture Trauma Allograft Bone Graft Substitute, Europe, 2018 – 2028 260 |
| Figure 7 36: Large Joint Reconstruction Allograft Bone Graft Substitute Units Sold by Anatomy, Europe, 2018 – 2028 261 |
| Figure 7 37: Units Sold by Country, Hip Large Joint Reconstruction Allograft Bone Graft Substitute, Europe, 2018 – 2028 262 |
| Figure 7 38: Units Sold by Country, Knee Large Joint Reconstruction Allograft Bone Graft Substitute, Europe, 2018 – 2028 263 |
| Figure 7 39: Units Sold by Country, Foot Reconstruction Allograft Bone Graft Substitute, Europe, 2018 – 2028 264 |
| Figure 7 40: Units Sold by Country, Craniomaxillofacial Allograft Bone Graft Substitute, Europe, 2018 – 2028 265 |
| Figure 7 41: Units Sold by Country, Oncology Allograft Bone Graft Substitute, Europe, 2018 – 2028 266 |
| Figure 7 42: Demineralized Bone Matrix Allograft Units Sold by Indication, Europe, 2018 – 2028 267 |
| Figure 7 43: Spine Demineralized Bone Matrix Allograft Units Sold by Anatomy, Europe, 2018 – 2028 268 |
| Figure 7 44: Units Sold by Country, Cervical Spine Demineralized Bone Matrix Allograft, Europe, 2018 – 2028 269 |
| Figure 7 45: Units Sold by Country, Thoracolumbar Spine Demineralized Bone Matrix Allograft, Europe, 2018 – 2028 270 |
| Figure 7 46: Trauma Demineralized Bone Matrix Allograft Units Sold by Anatomy, Europe, 2018 – 2028 271 |
| Figure 7 47: Units Sold by Country, Non-Union Trauma Demineralized Bone Matrix Allograft, Europe, 2018 – 2028 272 |
| Figure 7 48: Units Sold by Country, Fresh Fracture Trauma Demineralized Bone Matrix Allograft, Europe, 2018 – 2028 273 |
| Figure 7 49: Units Sold by Country, Craniomaxillofacial Demineralized Bone Matrix Allograft, Europe, 2018 – 2028 274 |
| Figure 7 50: Synthetic Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 275 |
| Figure 7 51: Spine Synthetic Bone Graft Substitute Units Sold by Anatomy, Europe, 2018 – 2028 276 |
| Figure 7 52: Units Sold by Country, Cervical Spine Synthetic Bone Graft Substitute, Europe, 2018 – 2028 277 |
| Figure 7 53: Units Sold by Country, Thoracolumbar Spine Synthetic Bone Graft Substitute, Europe, 2018 – 2028 278 |
| Figure 7 54: Trauma Synthetic Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 279 |
| Figure 7 55: Units Sold by Country, Non-Union Trauma Synthetic Bone Graft Substitute, Europe, 2018 – 2028 280 |
| Figure 7 56: Units Sold by Country, Fresh Fracture Trauma Synthetic Bone Graft Substitute, Europe, 2018 – 2028 281 |
| Figure 7 57: Large Joint Reconstruction Synthetic Bone Graft Substitute Units Sold by Anatomy, Europe, 2018 – 2028 282 |
| Figure 7 58: Units Sold by Country, Hip Large Joint Reconstruction Synthetic Bone Graft Substitute, Europe, 2018 – 2028 283 |
| Figure 7 59: Units Sold by Country, Knee Large Joint Reconstruction Synthetic Bone Graft Substitute, Europe, 2018 – 2028 284 |
| Figure 7 60: Units Sold by Country, Foot Reconstruction Synthetic Bone Graft Substitute, Europe, 2018 – 2028 285 |
| Figure 7 61: Units Sold by Country, Craniomaxillofacial Synthetic Bone Graft Substitute, Europe, 2018 – 2028 286 |
| Figure 7 62: Units Sold by Country, Oncology Synthetic Bone Graft Substitute, Europe, 2018 – 2028 287 |
| Figure 7 63: Leading Competitors by Country, Orthopedic Bone Graft Substitute Market, Europe, 2021 294 |
| Figure 8 1: Orthopedic Growth Factor Market by Segment, Europe, 2018 – 2028 (€M) 299 |
| Figure 8 2: Orthopedic Growth Factor Market by Segment, Europe, 2018 – 2028 (US$M) 300 |
| Figure 8 3: Orthopedic Growth Factor Market, Europe, 2018 – 2028 302 |
| Figure 8 4: Units Sold (5 cc) by Country, Orthopedic Growth Factor Market, Europe, 2018 – 2028 303 |
| Figure 8 5: Average Selling Price by Country, Orthopedic Growth Factor Market, Europe, 2018 – 2028 (€) 304 |
| Figure 8 6: Average Selling Price by Country, Orthopedic Growth Factor Market, Europe, 2018 – 2028 (US$) 305 |
| Figure 8 7: Market Value by Country, Orthopedic Growth Factor Market, Europe, 2018 – 2028 (€M) 306 |
| Figure 8 8: Market Value by Country, Orthopedic Growth Factor Market, Europe, 2018 – 2028 (US$M) 307 |
| Figure 8 9: Units Sold (5 cc) by Country, Spine Orthopedic Growth Factor Market, Europe, 2018 – 2028 309 |
| Figure 8 10: Units Sold (5 cc) by Country, Tibial Fracture Orthopedic Growth Factor Market, Europe, 2018 – 2028 311 |
| Figure 8 11: Leading Competitors by Country, Orthopedic Growth Factor Market, Europe, 2021 315 |
| Figure 9 1: Orthopedic Cell Therapy Market by Segment, Europe, 2018 – 2028 (€M) 321 |
| Figure 9 2: Orthopedic Cell Therapy Market by Segment, Europe, 2018 – 2028 (US$M) 322 |
| Figure 9 3: Platelet-Rich Plasma Market, Europe, 2018 – 2028 325 |
| Figure 9 4: Units Sold (10cc) by Country, Platelet-Rich Plasma Market, Europe, 2018 – 2028 326 |
| Figure 9 5: Average Selling Price by Country, Platelet-Rich Plasma Market, Europe, 2018 – 2028 (€) 327 |
| Figure 9 6: Average Selling Price by Country, Platelet-Rich Plasma Market, Europe, 2018 – 2028 (US$) 328 |
| Figure 9 7: Market Value by Country, Platelet-Rich Plasma Market, Europe, 2018 – 2028 (€M) 329 |
| Figure 9 8: Market Value by Country, Platelet-Rich Plasma Market, Europe, 2018 – 2028 (US$M) 330 |
| Figure 9 9: Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 332 |
| Figure 9 10: Units Sold (10cc) by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 333 |
| Figure 9 11: Average Selling Price by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 (€) 334 |
| Figure 9 12: Average Selling Price by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 (US$) 335 |
| Figure 9 13: Market Value by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 (€M) 336 |
| Figure 9 14: Market Value by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 (US$M) 337 |
| Figure 9 15: Units Sold by Country, Soft Tissue Platelet-Rich Plasma, Europe, 2018 – 2028 339 |
| Figure 9 16: Units Sold by Country, Spine Platelet-Rich Plasma, Europe, 2018 – 2028 340 |
| Figure 9 17: Units Sold by Country, Cardiac Platelet-Rich Plasma, Europe, 2018 – 2028 341 |
| Figure 9 18: Units Sold by Country, Orthopedic Platelet-Rich Plasma, Europe, 2018 – 2028 342 |
| Figure 9 19: Units Sold by Country, Plastics Platelet-Rich Plasma, Europe, 2018 – 2028 343 |
| Figure 9 20: Units Sold (10cc) by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 345 |
| Figure 9 21: Units Sold (10cc) by Country, Soft Tissue Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 346 |
| Figure 9 22: Units Sold (10cc) by Country, Trauma Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 347 |
| Figure 9 23: Units Sold (10cc) by Country, Joint Reconstruction Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 348 |
| Figure 9 24: Leading Competitors by Country, Orthopedic Cell Therapy Market, Europe, 2021 352 |
| Figure 10 1: Hyaluronic Acid Viscosupplementation Market by Segment, Europe, 2018 – 2028 (€M) 358 |
| Figure 10 2: Hyaluronic Acid Viscosupplementation Market by Segment, Europe, 2018 – 2028 (US$M) 359 |
| Figure 10 3: Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028 362 |
| Figure 10 4: Units Sold (Cycles) by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028 363 |
| Figure 10 5: Average Selling Price by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028 (€) 364 |
| Figure 10 6: Average Selling Price by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028 (US$) 365 |
| Figure 10 7: Market Value by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028 (€M) 366 |
| Figure 10 8: Market Value by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028 (US$M) 367 |
| Figure 10 9: Single-Injection Market, Europe, 2018 – 2028 369 |
| Figure 10 10: Units Sold (Cycles) by Country, Single-Injection Market, Europe, 2018 – 2028 370 |
| Figure 10 11: Average Selling Price by Country, Single-Injection Market, Europe, 2018 – 2028 (€) 371 |
| Figure 10 12: Average Selling Price by Country, Single-Injection Market, Europe, 2018 – 2028 (US$) 372 |
| Figure 10 13: Market Value by Country, Single-Injection Market, Europe, 2018 – 2028 (€M) 373 |
| Figure 10 14: Market Value by Country, Single-Injection Market, Europe, 2018 – 2028 (US$M) 374 |
| Figure 10 15: Two-Injection Market, Europe, 2018 – 2028 375 |
| Figure 10 16: Units Sold (Cycles) by Country, Two-Injection Market, Europe, 2018 – 2028 376 |
| Figure 10 17: Average Selling Price by Country, Two-Injection Market, Europe, 2018 – 2028 (€) 377 |
| Figure 10 18: Average Selling Price by Country, Two-Injection Market, Europe, 2018 – 2028 (US$) 378 |
| Figure 10 19: Market Value by Country, Two-Injection Market, Europe, 2018 – 2028 (€M) 379 |
| Figure 10 20: Market Value by Country, Two-Injection Market, Europe, 2018 – 2028 (US$M) 380 |
| Figure 10 21: Three-Injection Market, Europe, 2018 – 2028 381 |
| Figure 10 22: Units Sold (Cycles) by Country, Three-Injection Market, Europe, 2018 – 2028 382 |
| Figure 10 23: Average Selling Price by Country, Three-Injection Market, Europe, 2018 – 2028 (€) 383 |
| Figure 10 24: Average Selling Price by Country, Three-Injection Market, Europe, 2018 – 2028 (US$) 384 |
| Figure 10 25: Market Value by Country, Three-Injection Market, Europe, 2018 – 2028 (€M) 385 |
| Figure 10 26: Market Value by Country, Three-Injection Market, Europe, 2018 – 2028 (US$M) 386 |
| Figure 10 27: Five-Injection Market, Europe, 2018 – 2028 388 |
| Figure 10 28: Units Sold (Cycles) by Country, Five-Injection Market, Europe, 2018 – 2028 389 |
| Figure 10 29: Average Selling Price by Country, Five-Injection Market, Europe, 2018 – 2028 (€) 390 |
| Figure 10 30: Average Selling Price by Country, Five-Injection Market, Europe, 2018 – 2028 (US$) 391 |
| Figure 10 31: Market Value by Country, Five-Injection Market, Europe, 2018 – 2028 (€M) 392 |
| Figure 10 32: Market Value by Country, Five-Injection Market, Europe, 2018 – 2028 (US$M) 393 |
| Figure 10 33: Leading Competitors by Country, Hyaluronic Acid Viscosupplementation Market, Europe, 2021 399 |
| Figure 11 1: Orthopedic Cartilage Repair Market by Segment, Europe, 2018 – 2028 (€M) 404 |
| Figure 11 2: Orthopedic Cartilage Repair Market by Segment, Europe, 2018 – 2028 (US$M) 404 |
| Figure 11 3: Osteochondral Allograft Market, Europe, 2018 – 2028 406 |
| Figure 11 4: Meniscal Allograft Market, Europe, 2018 – 2028 407 |
| Figure 11 5: Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028 409 |
| Figure 11 6: Units Sold by Country, Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028 410 |
| Figure 11 7: Average Selling Price by Country, Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028 (€) 411 |
| Figure 11 8: Average Selling Price by Country, Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028 (US$) 412 |
| Figure 11 9: Market Value by Country, Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028 (€M) 413 |
| Figure 11 10: Market Value by Country, Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028 (US$M) 414 |
| Figure 11 11: Osteochondral Autograft Market, Europe, 2018 – 2028 415 |
| Figure 11 12: Leading Competitors, Orthopedic Cartilage Repair Market, Europe, 2021 419 |
iData’s 9-Step Research Methodology
Our reports follow an in-depth 9-step methodology which focuses on the following research systems:- Original primary research that consists of the most up-to-date market data
- Strong foundation of quantitative and qualitative research
- Focused on the needs and strategic challenges of the industry participants
Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.
Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.
Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.
Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.
Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.
Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.
Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.
Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.
Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.
Related Reports
